Gain Therapeutics will present Phase 1 results for GT-02287, their brain-penetrant small molecule drug candidate for Parkinson's disease, at the Michael J. Fox Foundation's 16th Annual Conference.
Gain Therapeutics announced positive topline results from its Phase 1 clinical trial of GT-02287, a novel small molecule therapy targeting GCase for Parkinson's disease.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.